Fluid Management Strategies on Blood Loss in Liver Transplantation

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-75
SponsorNational Taiwan University Hospital

About this trial

During liver transplantation, due to the complexity of the operation and abnormal coagulation function, there may be a large amount of bleeding and corresponding blood transfusion. Excessive blood transfusion will increase pulmonary complications and affect the prognosis. Infusion management to reduce bleeding is a very important issue in liver transplant surgery. Restrictive infusion management can effectively reduce the amount of bleeding in liver transplantation, but it remains unclear whether it will cause sequelae in other major organs.

The investigators plan to study different infusion goals and strategies in liver transplant surgery using a randomized group model, using the PiCCO (Pulse Contour Cardiac Output) cardiopulmonary volume monitor, and setting the stroke volume variation (SVV) as the macroscopic circulation.The purpose of this study was to divide it into restrictive and liberal groups to explore the impact on liver transplantation bleeding volume and inflammatory response as well as postoperative lung and renal function, and to collect statistics on clinical care and postoperative sequelae (pulmonary liver, renal function impairment, etc.) in order to develop the most appropriate infusion management strategy in liver transplantation.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

end stage liver disease

age between 18y/o to 75 y/o

expected to recieve to receive liver transplantation

Disqualifiers

arrythmia

Trial design

Design model

Parallel

Treatments tested in this trial

  • Liberal group

    Other intervention

    Fluid challage to keep stroke volume variation \< 10%

  • restrictive group

    Other intervention

    Fluid challage to keep stroke volume variation \< 18%

Treatment groups

60 Participants
are divided into 2 treatment groups
Group A: Liberal groupActive comparator 1 intervention
Group B: restrictive groupExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

blood loss intraoperatively

blood loss intraoperatively in liver transplant

Time frame
during the operation

Secondary outcomes

1

Lung injury biomarker

serum Clara Cell Protein (CC16)

Time frame
from biginning of the operation to postoprative day 1
2

Kidney injury biomarker

serum Neutrophil Gelatinase Associated Lipocalins (NGALs)

Time frame
from biginning of the operation to postoprative day 1
3

Influammatory reponses

IL-6

Time frame
from biginning of the operation to postoprative day 1

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.